Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Pneumococcal disease in the elderly - What is preventing vaccine efficacy?
Autore:
Rubins, JB; Janoff, EN;
Indirizzi:
Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA Univ Minnesota Minneapolis MN USA 55455 pt Med, Minneapolis, MN 55455 USA Vet Affairs Med Ctr, Minneapolis, MN USA Vet Affairs Med Ctr Minneapolis MN USA airs Med Ctr, Minneapolis, MN USA
Titolo Testata:
DRUGS & AGING
fascicolo: 5, volume: 18, anno: 2001,
pagine: 305 - 311
SICI:
1170-229X(2001)18:5<305:PDITE->2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
CAPSULAR POLYSACCHARIDE VACCINE; ANTIBODY-RESPONSE; STREPTOCOCCUS-PNEUMONIAE; PROTECTIVE EFFICACY; CLINICAL EFFICACY; IMMUNE-RESPONSE; IGG ANTIBODY; HIGH-RISK; BACTEREMIA; ADULTS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Rubins, JB Vet Affairs Med Ctr, 1 Vet Dr, Minneapolis, MN 55417 USA Vet Affairs Med Ctr 1 Vet Dr Minneapolis MN USA 55417 55417 USA
Citazione:
J.B. Rubins e E.N. Janoff, "Pneumococcal disease in the elderly - What is preventing vaccine efficacy?", DRUG AGING, 18(5), 2001, pp. 305-311

Abstract

The effective prevention of Streptococcus pneumoniae infection has a renewed priority in an era in which the emergence of antibacterial-resistant strains has the potential to further compromise efforts to reduce early mortality from invasive pneumococcal infection. Although the 23-valent pneumococcal polysaccharide (PPS) vaccine was approved in the US to prevent respiratory and invasive infection in the elderly and other high-risk populations, the protective efficacy of this vaccine for the growing population of adultsaged > 65 years remains controversial. The apparent effectiveness of pneumococcal immunisation in clinical studies of elderly adults has varied depending upon whether a reduction in pneumococcal colonisation, pneumonia, bacteraemia or death was used as an outcome. Clinical studies of vaccine efficacy to date suggest that the current pneumococcal vaccine is 56 to 81% effective at preventing invasive pneumococcalinfection, and may have additive benefit to influenza vaccine in preventing community-acquired pneumonia. particularly in elderly adults with an increased risk of serious pneumonia requiring hospitalisation. Possible reasonsfor incomplete protection from pneumococcal infection after immunisation include infection with non-vaccine serotypes, inadequate or ineffective antibody responses, waning of antibody responses, or compromised nonhumoral host defences. Fur ther studies are needed to determine whether: (i) elderly adults who respond poorly to the 23-valent pneumococcal vaccine can be identified prior to immunisation and targeted for study with improved pneumococcal vaccines; (ii) specific nutrient deficiencies can be identified and corrected to improve the immune responsiveness of elderly adults to the PPS vaccine; (iii) newer protein-conjugate or DNA pneumococcal vaccines may be more uniformly immunogenic for elderly adults; and (iv) whether smoking cessation reduces the risk of invasive pneumococcal infection in elderly adults.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 06:32:04